제약 허브 및 환자 접근 지원 서비스 시장 규모, 점유율, 동향 분석 보고서 : 서비스 유형별, 제공 유형별, 지역별, 부문별 예측(2025-2033년)

Pharma Hub And Patient Access Support Service Market Summary

The global pharma hub and patient access support service market size was estimated at USD 3.24 billion in 2024 and is projected to reach USD 7.63 billion by 2033, growing at a CAGR of 10.0% from 2025 to 2033. The growth is attributed to the increasing need to administer new medicines for various specialties and rare & orphan diseases, prioritizing creating a patient-centric ecosystem.

Payer-side complexity (prior authorizations, specialty drug formularies, and rising claim denials), and tighter affordability controls have pushed manufacturers to outsource patient onboarding, benefiting verification and copay/cost-assistance management to dedicated hub providers.

The growing launch of high-cost specialty and rare-disease therapies between 2021 and 2024 has become a key driver for the expansion of pharma hubs and patient access support services. According to the U.S. FDA, 37 novel drugs were approved in 2022, of which 20 around 54% were targeted at rare diseases, while in 2023, 55 new drugs were approved, and over half, 28 drugs, were for rare diseases. These therapies often carry exceptionally high price tags and require complex insurance approvals.

Hemgenix, a gene therapy for hemophilia B approved in 2022, was priced at about USD 3.5 million per dose, and Alzheimer's drug Leqembi, approved in 2023, costs around USD 26,500 annually. Such launches highlight the growing financial and administrative barriers for patients, encouraging pharmaceutical companies to invest heavily in digital hub platforms, benefit verification systems, prior authorization automation, and patient support programs. As a result, the increasing number of specialized, high-cost therapies is directly driving demand for integrated pharma hub and patient access support solutions to streamline reimbursement, accelerate therapy initiation, and improve adherence outcomes.

The market is further driven by players undertaking several strategic initiatives. For instance, in November 2023, Docquity announced the expansion of its digitized patient access program, DocquityCare PAP, to Thailand. It launched five PAPs in Thailand, supporting 250 authorized HCPs and around 100 enrolled hospitals to enhance patient care for individuals with cancer and additional life-threatening conditions.

Global Pharma Hub And Patient Access Support Service Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharma HUB and patient access support service market report based on service type, service delivery type, and region:

• Service Type Outlook (Revenue, USD Million, 2021 - 2033)
• Program Enrollment
  • Order processing
  • Application processing
  • Ease of enrollment (through phone, face, portal, or app)
  • Program data
• Treatment Navigators
  • Process flows and standard operating procedures
  • Program literature and scripts
  • Care team training
  • Systems testing and optimization
• Reimbursement Services/Affordability Services
• Clinical Educator
• Coordination of Specialty Pharmacy/Dispensing
• Others
• Service Delivery Type Outlook (Revenue, USD Million, 2021 - 2033)
• Integrated Services
• Standalone Services
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service Type
  • 1.2.2. Service Delivery Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Launch of Specialty and Rare-Disease Therapies
    • 3.2.1.2. Need to Simplify Patient Enrollment and Therapy Access
    • 3.2.1.3. Growing Emphasis on Patient-Centric Care
    • 3.2.1.4. Increasing Regulatory and Compliance Requirements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High implementation and operational costs
    • 3.2.2.2. Data Privacy and Regulatory Compliance Challenges
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Technology Overview
  • 3.2.6. Case Studies
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Pharma HUB and Patient Access Support Service Market: Service Type Estimates & Trend Analysis

• 4.1. Service Type Segment Dashboard
• 4.2. Service Type Market Share Movement Analysis, 2024 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
• 4.4. Program Enrollment
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Order processing
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Application processing
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
    • 4.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Program data
    • 4.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Treatment Navigators
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Process flows and standard operating procedures
    • 4.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Program literature and scripts
    • 4.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Care team training
    • 4.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Systems testing and optimization
    • 4.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Reimbursement Services/Affordability Services
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Clinical Educator
  • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Coordination of Specialty Pharmacy/Dispensing
  • 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharma HUB and Patient Access Support Service Market: Delivery Type Estimates & Trend Analysis

• 5.1. Delivery Segment Dashboard
• 5.2. Delivery Market Share Movement Analysis, 2024 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Delivery, 2021 to 2033 (USD Million)
• 5.4. Integrated Services
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Standalone Services
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharma HUB and Patient Access Support Service Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market: Key Takeaways
• 6.3. North America
  • 6.3.1. North America Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamic
    • 6.3.2.2. Regulatory framework
    • 6.3.2.3. Competitive insights
    • 6.3.2.4. U.S. Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamic
    • 6.3.3.2. Regulatory framework
    • 6.3.3.3. Competitive insights
    • 6.3.3.4. Canada Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamic
    • 6.3.4.2. Regulatory framework
    • 6.3.4.3. Competitive insights
    • 6.3.4.4. Mexico Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamic
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive insights
    • 6.4.2.4. Germany Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. UK
    • 6.4.3.1. Key country dynamic
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive insights
    • 6.4.3.4. UK Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamic
    • 6.4.4.2. Regulatory framework
    • 6.4.4.3. Competitive insights
    • 6.4.4.4. France Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamic
    • 6.4.5.2. Regulatory framework
    • 6.4.5.3. Competitive insights
    • 6.4.5.4. Italy Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamic
    • 6.4.6.2. Regulatory framework
    • 6.4.6.3. Competitive insights
    • 6.4.6.4. Spain Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key country dynamic
    • 6.4.7.2. Regulatory framework
    • 6.4.7.3. Competitive insights
    • 6.4.7.4. Denmark Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key country dynamic
    • 6.4.8.2. Regulatory framework
    • 6.4.8.3. Competitive insights
    • 6.4.8.4. Sweden Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key country dynamic
    • 6.4.9.2. Regulatory framework
    • 6.4.9.3. Competitive insights
    • 6.4.9.4. Norway Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key country dynamic
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive insights
    • 6.5.2.4. Japan Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key country dynamic
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive insights
    • 6.5.3.4. China Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamic
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive insights
    • 6.5.4.4. India Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamic
    • 6.5.5.2. Regulatory framework
    • 6.5.5.3. Competitive insights
    • 6.5.5.4. South Korea Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Australia
    • 6.5.6.1. Key country dynamic
    • 6.5.6.2. Regulatory framework
    • 6.5.6.3. Competitive insights
    • 6.5.6.4. Australia Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key country dynamic
    • 6.5.7.2. Regulatory framework
    • 6.5.7.3. Competitive insights
    • 6.5.7.4. Thailand Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Pharma HUB and Patient Access Support Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamic
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive insights
    • 6.6.2.4. Brazil Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamic
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive insights
    • 6.6.3.4. Argentina Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key country dynamic
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive insights
    • 6.7.2.4. South Africa Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key country dynamic
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive insights
    • 6.7.3.4. Saudi Arabia Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamic
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive insights
    • 6.7.4.4. UAE Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamic
    • 6.7.5.2. Regulatory framework
    • 6.7.5.3. Competitive insights
    • 6.7.5.4. Kuwait Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis/Company Market Share Analysis (2024)
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Valeris (Formerly PharmaCord)
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Product benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. Fortrea
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Product benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. AssistRx
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Product benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. CareMetx, LLC
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Product benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. ConnectiveRx
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Product benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. Lash Group
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Product benchmarking
    • 7.5.6.4. Strategic initiatives
  • 7.5.7. McKesson Corporation
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Engage
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Cardinal Health
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. Envoy Health, Inc.
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Product benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. EVERSANA
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Product benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. United BioSource LLC
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Product benchmarking
    • 7.5.13.4. Strategic initiatives
  • 7.5.14. Mercalis
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial performance
    • 7.5.14.3. Product benchmarking
    • 7.5.14.4. Strategic initiatives
  • 7.5.15. Sciensus
    • 7.5.15.1. Overview
    • 7.5.15.2. Financial performance
    • 7.5.15.3. Product benchmarking
    • 7.5.15.4. Strategic initiatives